Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance Aug 1, 2025
Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading Jul 29, 2025
Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update Jun 30, 2025
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference Jun 19, 2025
New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society May 28, 2025
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 May 26, 2025
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update May 13, 2025
Poxel Provides Financial Update for the First Quarter 2025 and Announces the Postponement of its 2024 Full-Year Results Apr 16, 2025
Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment Apr 8, 2025
